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Abstract The emergent interest in cancer epigenetics stems
from the fact that epigenetic modifications are implicated in
virtually every step of tumorigenesis. More interestingly,
epigenetic changes are reversible heritable changes that are
not due to the alteration in DNA sequence but have
potential to alter gene expression. Dietary agents consist
of many bioactive ingredients which actively regulate
various molecular targets involved in tumorigenesis. We
present evidence that numerous bioactive dietary compo-
nents can interfere with various epigenetic targets in cancer
prevention and therapy. These agents include curcumin
(turmeric), genistein (soybean), tea polyphenols (green tea),
resveratrol (grapes), and sulforaphane (cruciferous vegeta-
bles). These bioactive components alter the DNA methyl-
ation and histone modifications required for gene activation
or silencing in cancer prevention and therapy. Bioactive
components mediate epigenetic modifications associated
with the induction of tumor suppressor genes such as
p21
WAF1/CIP1 and inhibition of tumor promoting genes such
as the human telomerase reverse transcriptase during
tumorigenesis processes. Here, we present considerable
evidence that bioactive components and their epigenetic
targets are associated with cancer prevention and therapy
which should facilitate novel drug discovery and develop-
ment. In addition, remarkable advances in our understanding
of basic epigenetic mechanisms as well as the rapid progress
that is being made in developing powerful new technologies,
such as those for sensitive and quantitative detection of
epigenetic and epigenomic changes in cancer biology, hold
great promise for novel epigenetic approaches to cancer
prevention and therapy.
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Introduction
Natural dietary agents including fruits, vegetables, and
spices have been showing great potential in preventing and
treating a wide variety of diseases including cancers.
Dietary agents consist of many bioactive compounds that
are ubiquitous in plants, many of which have been used as
ancient traditional medicines. Dietary agents are not only an
excellent source of fiber, vitamins, and minerals, but also
contain bioactive components such as polyphenols, alka-
loids, and phenolics that may serve more than a basic
nutrition function. The bioactive components of dietary
phytochemicals most often shown to be effective against
cancer are tea polyphenols, genistein, curcumin, resveratrol,
sulforaphane, isothiocyanates, silymarin, diallyl sulfide,
lycopene, rosmarinic acid, apigenin, and gingerol. These
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DOI 10.1007/s13148-010-0011-5bioactive components have shown great potential in
preventing cancer through modifying genetic and epigenet-
ic targets. In this analysis, we will focus on epigenetic
targets of these bioactive dietary supplements associated
with cancer prevention and therapy.
Epigenetics and cancer
“Geneticists study the gene; however, for epigeneticists,
there is no obvious ‘epigene’” (Bird 2007). Nevertheless,
epigenetics is typically defined as the study of reversible
heritable changes in gene expression that are not due to
alterations in DNA sequence. The term ‘epigenetic’ was
coined by the developmental biologist, Conrad Hal
Waddington, in 1942. Robin Holliday defined epigenetics
as the study of the mechanisms of temporal and spatial
control of gene activity during the development of complex
organisms (Holliday 1990). One of the best examples of
epigenetic changes in eukaryotic biology is the different
developmental stages from the single fertilized egg, the
zygote, to a fully grown organism. Modern biology uses
epigenetic changes as molecular tools for finding and
treating various diseases including cancer. Cancer is a
multi-step process derived from combinational crosstalk
between genetic alterations and epigenetic influences
through various environmental factors (Ducasse and Brown
2006;E s t e l l e r2008; Ellis et al. 2009). Moreover, it has been
well documented that environmental exposure to nutritional,
dietary, physical, and chemical factors could alter gene
expression and modify individual genetic susceptibility
through changes in the epigenome (Issa 2008; Suter and
Aagaard-Tillery 2009;H e r c e g2007). Several distinct but
intertwined mechanisms are known to be part of the
epigenome which includes DNA methylation, histone
acetylation, poly-ADP-ribosylation and ATP-dependent
chromatin remodeling.
Epigenetic mechanisms controlling gene transcription
are often involved in cell proliferation, differentiation, and
survival and are casually linked with malignant development.
Alterations in epigenetic processes including chromatin
modifications such as DNA methylation and histone
acetylation are commontargetsstudiedincancerepigenomics
(Herceg 2007;E s t e l l e r2007). It has been shown that half of
all tumor suppressor genes are inactivated in cancers more
often by epigenetic, than by genetic, mechanisms (Issa
2008). Growing evidence suggests that bioactive dietary
components impact epigenetic processes often involved with
reactivation of tumor suppressor genes, activation of cell
survival proteins, and induction of cellular apoptosis in many
types of cancer (Landis-Piwowar et al. 2008;L ie ta l .2010;
Paluszczak et al. 2010; Majid et al. 2008). In addition to
transcriptional silencing of tumor suppressor genes and
protein expression, noncoding microRNAs (miRNAs) can
regulate expression of a myriad of cellular proteins by
affecting mRNA stability and translation by epigenetic
processes in cancer progression (Esteller 2007;D u c a s s e
and Brown 2006). Interestingly, these miRNAs can control
the expression of various epigenetic modifying enzymes
such as DNA methyltransferases (DNMTs), histone methyl-
transferases (HMTs), and histone deacetylases (HDACs)
involved in carcinogenesis processes (Guil and Esteller
2009;S a i t oa n dJ o n e s2006). Recent evidence suggests that
bioactive dietary components can also target various onco-
genic or tumor suppressive miRNAs to alter the gene
expression profile in cancer prevention (Parker et al. 2009;
Sun et al. 2009;L ie ta l .2009b). In fact, miRNA profiles are
now being used to classify human cancers (Calin et al.
2004). Further, miRNAs can directly or indirectly regulate
cancer progression either by acting as tumor suppressors or
by altering epigenetic modifying enzymes, respectively. In
particular, miRNA-221 and miRNA-222 target KIT,a n
oncogene, and therefore function as tumor suppressors in
erythroblastic cells and other human solid tumors (Croce
2009). Furthermore, the miRNA-29 family can directly
regulate the expression of DNMTs and increase expression
of DNMT3a and DNMT3b thereby causing a global
genomic hypermethylation and silencing of methylation-
sensitive tumor suppressor genes such as FHIT and WWOX
(Fabbri et al. 2007).
DNA methylation
DNA methylation involves the covalent addition of a
methyl group to cytosines in eukaryotic DNA. DNA
methylation typically occurs at CpG dinucleotides, whereas
non-CpG methylation is often found in embryonic stem
cells. Moreover, 60–90% of all dispersed CpG sequences
are methylated in mammals, whereas, unmethylated CpGs
are grouped in clusters called “CpG islands” that are
present in the 5′-regulatory regions of many genes. The
DNA methylation state is maintained primarily by DNMTs,
which catalyze the transfer of a methyl group from the
methyl precursor, S-adenosyl-L-methionine (SAM), onto
the 5-position of certain cytosines in CpG dinucleotides
(Fig. 1). Multiple DNMTs are known to be present in
humans, animals, and microorganisms, and they have
varying degrees of specificity toward unmethylated and
hemimethylated DNA substrates (Bestor 2000). SAM is
the methyl donor in DNMT-mediated DNA methylation,
as in many other enzymatic methylation reactions [such
as the catechol-O-methyltransferase (COMT)-mediated
O-methylation of various catechol substrates], resulting
in the formation of S-adenosyl-L-homocysteine (SAH)
after donating its methyl group to the DNA substrate.
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CpG islands acquire abnormal hypermethylation by altering
DNMT expression and activity, which results in heritable
transcriptional gene silencing. DNA methylation may
impact the transcription of genes in two major ways. First,
the methylation of DNA prevents binding of sequence
specific transcriptional factors (e.g., AP-2, E2F, c-Myc) that
require the presence of unmethylated CpG within the
binding sites (Tate and Bird 1993). Second and likely more
important is that methylated DNA may be bound by
proteins known as methyl-CpG-binding domain (MBD)
proteins. MBD proteins then recruit additional proteins,
such as histone deacetylases and other chromatin-
remodeling proteins that can modify acetylation and
methylation status of histones to the locus thereby inhibit-
ing transcriptional access to the chromatin. This subse-
quently leads to the formation of compact, inactive
chromatin (Wade 2001; Ballestar and Wolffe 2001). The
clinical aspects of DNA methylation are very important
especially since DNA methylation is a reversible process and
thereby leads to silencing or activation of particular genes for
disease progression including cancer (Laird 2005).
In higher eukaryotes, DNA methylation is an enzymatic
process that is primarily mediated by three enzymes;
DNMT1, DNMT3a, and DNMT3b (Bestor 2000). DNMT1
is a ubiquitous enzyme considered the major methyltrans-
ferase for maintenance methylation, and the other two
DNMTs serve as de novo methyltransferases. In human cells,
DNMTs have some overlap in de novo and maintenance
function. DNMTs have been showed to be an extensive
molecular drug target for many available FDA-approved
epigenetic drugs such as 5-azacytidine, commercially avail-
able as Vidaza, and 5-aza-2′-deoxycytidine, commercially
available as Dacogen (Grønbaek et al. 2007; Kaminskas et
al. 2005). In addition, the DNMT1 antisense oligonucleotide
referred to as MG98 is currently under phase I clinical trials
for patients with advanced solid tumors (Plummer et al.
2009). However, many of the most commonly used drugs
DNMTs
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Fig. 1 Schematic diagram
illustrating DNA methylation
catalyzed by DNMTs. a The
DNA methylation process is
catalyzed by the DNMTs by
adding a methyl group (CH3)
from SAM to the 5-position
of the cytosine ring. SAM
donates a methyl group and is
then converted into SAH. b
Methylated cytosine moieties
in CpG dinucleotides within a
gene promoter. c DNMTs
convert unmethylated DNA
into methylated DNA in
chromatin. White circles
unmethylated CpG sites, green
circles hypermethylated CpG
sites, yellow circles histone
proteins, red thread DNA
Clin Epigenet (2010) 1:101–116 103produce meaningful results in less than half of the patients,
and the use of higher doses often results in adverse side
effects (Grønbaek et al. 2007). Another derivative of 5-
azacytidine, zebularine, appears to be more stable than 5-
azacytidine or 5-aza-2′-deoxycytidine, but has very narrow
specificity towards cancer cells (Hellebrekers et al. 2007).
Therefore, many cancer patients are exposed to highly toxic
drugs and suffer from adverse side effects while receiving
few therapeutic benefits (Eisenberg et al. 1998). Hence non-
toxic and more effective dietary bioactive components have
received wide attention in the use against various cancers for
prevention and therapy. Extensive results have shown that
bioactive dietary components have great potential in altering
DNA methylation by modifying DNMTs levels in cancer
prevention and therapy (Li and Tollefsbol 2010).
Epigenetic regulation has attracted considerable interest
as a molecular target for cancer prevention and therapy as
well as a target of bioactive food components. Many
bioactive dietary components have shown promising results
in direct or indirect inhibition of DNMT activity in cancer
prevention and therapy. For example, (−)-epigallocatechin-
3-gallate (EGCG), a major component of green tea, is
known to complex with the DNMTs which reduces
methylating activity in cancer cells leading to cancer
prevention or therapy through epigenetic mechanisms
(Fang et al. 2003; Mittal et al. 2003; Tsao et al. 2009).
Furthermore, daily oral intake of EGCG in the form of
Polyphenon E, a green tea extract, was well tolerated by
chronic lymphocytic leukemia patients in phase I clinical
trials (Shanafelt et al. 2009).
Histone modifications
Many histone modifications play important roles in
epigenetic alterations, and acetylation and methylation are
the two main histone modifications that have been
clinically linked as predictors for cancer progression (Davis
and Ross 2007; Fraga et al. 2005; Seligson et al. 2005).
These histone modifications induce chromatin alterations
that allow access to the various transcriptional activators
and/or repressors at gene promoters, and they therefore play
an important role in gene regulation and tumorigenesis
(Fig. 2) (Ganesan et al. 2009; Dalvai and Bystricky 2010;
Sharma et al. 2010). Histones are subject to different
types of reversible covalent posttranslational modifications
including, but not limited to, lysine acetylation, lysine and
arginine methylation, serine and threonine phosphorylation,
and lysine ubiquitination and sumoylation. These modifica-
tions occur primarily within the histone amino-terminal tails
protruding from the surface of the nucleosome as well as on
the globular core region and regulate key cellular processes
such as transcription, replication, and repair (Kouzarides
2007). Specific histone modifications appear to act as
programmed “codes” which can be identified by specific
proteins to bring about distinct downstream events such as
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Fig. 2 Schematic representation
of histone modifications. HATs
induce relaxed chromatin which
allows access to the various
transcriptional factors associated
with gene activation. HDACs
induce closed chromatin
associated with gene activation.
Various bioactive compounds
such as EGCG, sulforaphane,
and curcumin are linked with
alterations of both HATs and
HDACs. Yellow circle histone
protein, red thread DNA; AC
acetylation, TF transcription
factor
104 Clin Epigenet (2010) 1:101–116transcriptional activation or repression. The mechanism of
inheritance of this histone code, however, is still not fully
understood.
DNA methylation often suppresses gene expression,
with some exceptions like the human telomerase reverse
transcriptase (hTERT) gene (Berletch et al. 2008; Li et al.
2009a). Nevertheless, gene repression or activation is not
determined by histone acetylation or methylation in
general, but rather is determined by which residue is being
modified, for example, trimethylation of lysine 4 on histone
H3 (H3K4me3)isenrichedfortranscriptionalgeneactivation,
whereas trimethylation of lysine 9 on histone H3 (H3K9me3)
and trimethylation of lysine 27 on histone H3 (H3K27me3) is
present at gene promoters for transcriptional repression
(Hebbes et al. 1988; Choudhuri et al. 2010). Further,
enrichment of acetylation at lysine residues at gene promoter
regions is associated with gene activation (Hebbes et al.
1988). Histone acetylation enhances chromatin accessibility
by neutralizing the DNA–histone interactions which results
in a relaxed, open chromatin conformation that allows the
transcriptional activators to gain access to their cognate
recognition elements and initiate/enhance transcription
(Fig. 2)( G ö r i s c he ta l .2005; Lafon-Hughes et al. 2008).
Histone modifications are catalyzed by many enzymes
such as histone acetyltransferases (HATs), histone deacety-
lases (HDACs), histone methyltransferases (HMTs), and
histone demethylases (HDMs). HATs and HDACs add and
remove acetyl group to the lysine residues present in
histones, respectively, whereas HMTs and HDMs add and
remove methyl groups to the different lysine or arginine
resides in histones, respectively (Choudhuri et al. 2010).
Further, arginine methylation is presumably transcription
activating, whereas lysine methylation can cause either
transcriptional activation or repression, depending on which
lysine residue is being methylated (Choudhuri et al. 2010).
Histone hypoacetylation at a promoter region, induced by
either lack of HAT function or increased HDAC activity,
results in silencing of the tumor suppressor gene, p21
WAF1/CIP1,
in tumorigenesis (Majid et al. 2008;K i k u n oe ta l .2008).
By contrast, histone hyperacetylation at certain promoters
through either increased HAT activity or decreased HDAC
activity, results in an activation of normally repressed
genes (Acharya et al. 2005;K i me ta l .2003). Collectively,
the aberrant enrichment of HAT and HDAC activities may
trigger carcinogenesis processes (Mottet and Castronovo
et al. 2008).
It has been widely recognized that HDACs are promis-
ing targets in the field of oncology and epigenetic therapy
(Davis and Ross 2007; Marsoni et al. 2008). An impressive
body of preclinical research points to the ability of HDAC
inhibitors (HDACIs) to modulate a wide variety of cellular
functions, including cellular differentiation, cell cycle
progression, apoptosis, cytoskeleton modifications, and
angiogenesis (Marsoni et al. 2008). Thus, the use of
HDACIs is considered a potent strategy in cancer prevention
and epigenetic therapy. Anextensive list ofHDACIs has been
purified from natural sources or synthetically developed, and
manyoftheseHDACIshaveadvancedtoclinicalapplications
(Bolden et al. 2006). HDACIs such as trapoxin, trichostatin
A, and suberoylanilide hydroxamic acids (SAHAs) are
among the most studied and have more global HDAC
inhibition activity. Vorinostat or SAHA (brand name
Zolinza) is a commercially available FDA-approved HDACI
for treatment of cutaneous T-cell lymphoma (Ellis et al.
2009). Many other HDACIs are in different phases of
clinical trials such as panobinostat (LBH589), belinostat
(PXD101), TF2357, PCI-24781, phenylbutyrate, romidepsin
(depsipeptide), MS-275, MS-275 and, MGCD0103 (Ellis et
al. 2009).
Besides synthetic HDACIs, many bioactive dietary
components have shown promising results in direct or
indirect inhibition of HDAC activity as well as other
histone modification activities in cancer prevention and
therapy (Nian et al. 2009; Myzak et al. 2006c). For
example, sulforaphane (SFN), a major component present
in cruciferous vegetables, inhibits HDAC activity, at least
partially, by direct interaction with the HDAC active sites
(Myzak et al. 2004). In an another study, SFN has been
shown to result in HDAC inhibition in human volunteers
consuming SFN-rich broccoli sprouts, and the SFN-induced
HDAC inhibition increased histone acetylation in peripher-
al blood cells of the human subjects without adverse effects
(Myzak et al. 2006a, 2007).
Bioactive dietary components and epigenetic targets
For more than a decade, there has been considerable
interest in the use of naturally occurring botanicals for the
prevention of diseases, including cancers. Beverages, fruits,
vegetables, and other components of the human diet
commonly contain polyphenols which have been shown
in many investigations to have chemopreventive and anti-
cancer properties (Aggarwal and Shishodia 2006; Meeran
and Katiyar 2008; Yang et al. 2001). Different nutrients,
specifically dietary botanicals, can play a role in the
regulation of both normal and pathologic processes. An
improved understanding of the regulatory role of these
nutrients on various molecular targets may help in the
prevention and treatment of various cancers. Although
several dietary agents or nutrients regulate different
molecular targets in various cancers, here we summarize
the role of some common bioactive dietary agents and their
epigenetic targets on various cancers. The agents which we
discuss include tea polyphenol–catechins (green tea),
curcumin (turmeric), genistein (soybean), resveratrol
Clin Epigenet (2010) 1:101–116 105(grapes), SFN (cruciferous vegetables), and other bioactive
components such as apigenin (parsley), baicalein (Indian
trumpet), cyanidins (grapes), isothiocyanate (cruciferous
vegetables), rosmarinic acid (rosemary), and silymarin
(milk thistle). A brief discussion includes their epigenetic
targets in cancer cells both in vitro and in vivo leading to
their multiple roles in the regulation of cancer prevention
and therapy. Some of the most commonly used bioactive
dietary components, including their source, botanical name,
and their epigenetic targets associated with tumorigenesis
are summarized in Table 1.
Tea polyphenols
DNA methylation
The tea plant Camellia sinesis is cultivated in more than 30
countries. Tea is consumed worldwide and next to water is
the most consumed beverage in the world, with an average
per capita consumption of ~120 mL/day (Mukhtar and
Ahmad 2000). Epidemiologic observations and laboratory
studies have indicated that polyphenolic compounds present
in tea may reduce the risk of a variety of diseases, including
coronary heart disease and cancer. The most abundant
chemical compound in green tea beverages is catechins,
which include (−)-epicatechin (EC), (−)-epicatechin-3-gallate
(ECG),(−)-epigallocatechin(EGC),and(−)-epigallocatechin-
3-gallate (EGCG) (Graham 1992). Of these, EGCG accounts
for more than 50% of the total polyphenol and effective
content in green tea (Lin and Liang 2000). EGCG has been
identified as a major and most effective constituent of green
tea. Therefore, the large majority of the in vitro and in vivo
studies of the effects of green tea have been conducted using
EGCG.
EGCG has been shown to induce apoptosis and cell
cycle arrest in many cancer cells without affecting normal
cells (Ahmad et al. 1997; Gu et al. 2009). Therefore, it is
likely that EGCG imparts its anti-cancer effects through
many different mechanisms (Balasubramanian et al. 2010;
Fassina et al. 2004; Huh et al. 2004). One mechanism
includes the inhibition of DNMT1 leading to demethylation
and reactivation of methylation-silenced genes. Treatment
of human esophageal KYSE 510 and 150 cells with EGCG
has been shown to lower DNMT1 activity and to lead to
hypomethylation and re-expression of genes including
p16
INK4a, retinoicacidreceptorβ(RARβ), O
6-methylguanine
methyltransferase (MGMT), and human mutL homologue 1
(hMLH1) (Fang et al. 2003). In another study with oral
carcinoma cells, EGCG partially reversed the hypermethyla-
tion status of RECK, a tumor suppressor gene, and
significantly enhanced the expression level of RECK
mRNA. EGCG-induced epigenetic reactivation of RECK is
important since it negatively regulates matrix metalloprotei-
nases (MMPs) and inhibits tumor invasion, angiogenesis, and
metastasis (Kato et al. 2008). Pandey et al. (2010) demon-
strated that exposure of human prostate cancer LNCaP cells
to 1–10 μg/ml of green tea polyphenol for 1–7 days caused a
concentration- and time-dependent re-expression of a known
precursor to the genesis of prostate cancer, gluthathione-S-
transferase pi (GSTP1), which correlated with DNMT1
inhibition.
Recently, it has been observed that tea polyphenols
[catechin, epicatechin, and EGCG and bioflavonoids
(quercetin, fisetin, and myricetin)] inhibited SssI DNMT-
and DNMT1-mediated DNA methylation in a concentration-
dependent manner. The IC50 values for catechin, epicatechin,
and various flavonoids ranged from 1.0 to 8.4 μM, but
EGCG was a more potent inhibitor, with IC50 values ranging
from 0.21 to 0.47 μM( L e ee ta l .2005). A molecular
modeling study demonstrated that EGCG exerts its inhibitory
effect on DNMT1 function by blocking entry of the key
nucleotidecytosineintoits activesitebyhydrogenbonds and,
thus, prevents DNA methylation (Fang et al. 2003). Further-
more, the presence of Mg
2+ can enhance the binding force of
EGCG and the DNMTs by stabilizing their binding
interactions nearly ten times more than without Mg
2+
presence (Lee et al. 2005). Here, we discuss most of the
epigenetic targets altered by EGCG, but other catechins such
as EC, ECG, and EGC have also been found to share similar
properties although they are less efficient than EGCG
(Fang et al. 2003; Lee et al. 2005).
Besides direct inhibition of DNMT by EGCG, it was
also reported that consumption of polyphenols could lead to
a decrease in available S-adenosyl-L-methionine (SAM)
and an increase in S-adenosyl-L-homocysteine (SAH) and
homocysteine levels, thereby providing evidence of an
indirect inhibition of DNA methylation by EGCG (Lee
and Zhu 2006). This conjecture is supported by animal
studies demonstrating that EGCG consumption through
drinking water can moderately decrease the level of SAM
(without increasing the level of SAH) in the intestine
(Fang et al. 2007).
EGCG not only reactivates tumor suppressor genes by
inhibiting DNA methylation but also inhibits tumor
promoter genes such as hTERT, a catalytic subunit of
telomerase (Berletch et al. 2008). In most cases, hyper-
methylation of the regulatory region of a gene can inhibit
its expression. For example, the p16
INK4a promoter
becomes methylated during tumorigenesis leading to
inhibition of its expression (Lee et al. 2003). Interestingly,
hTERT regulation by DNA methylation goes against the
paradigm, and hypermethylation of its promoter leads to
increased expression in cancer cells (Guilleret and Benhat-
tar 2004; Quante et al. 2005). One possible reason for this
paradox was shown in breast cancer cells were EGCG-
106 Clin Epigenet (2010) 1:101–116O
O
HO
OH O
SH
O O
H3CO
HO
OCH3
OH
O HO
OH
O
OH
OH
OH
C
O
OH
OH
OH
O HO
OH O
OH
CH3
CH3
CH3 CH3 CH3
CH3 CH3 CH3
H3C
CH3
HO
OH
OH
O HO
OH
H
H
OH
O
O
H
CH2OH
OC3H
OH
O
H
S
N
O
C
S
*limited references given, full list available in text
1 Source
2 Botanical name
Table 1 Bioactive dietary
compounds—their source,
molecular structure, and
epigenetic targets
Clin Epigenet (2010) 1:101–116 107induced progressive demethylation of the hTERT promoter
which allowed the E2F-1 repressor of hTERT to bind to its
promoter and inhibit its expression (Berletch et al. 2008).
Another classical example for EGCG-induced promoter
demethylation inhibiting an oncogene is Wingless-type
(Wnt) which occurs through epigenetic reactivation of
Wnt inhibitory factor-1 (WIF-1) in lung cancer cells (Gao
et al. 2009). The Wnt family consists of a group of
signaling molecules that is extensively involved in develop-
mentalprocessesandoncogenesis.WIF-1 is a Wnt antagonist
that inhibits Wnt signaling by direct binding to Wnt
molecules (Gao et al. 2009).
EGCG is unstable under physiological conditions, and
methylation of EGCG by COMT is a modification that
reduces the biological activity of EGCG (Landis-Piwowar
et al. 2010). Recently, Moiseeva et al. (2007) showed that
low-dose long-term exposure of bioactive components such
as EGCG and genistein results in epigenetic alterations of
gene expression, reduced growth, and increased cellular
apoptosis in breast cancer cells. Furthermore, there are
several synthetic analogs of EGCG that have been shown to
have strong anti-cancer activity with more efficacy and
stability than EGCG under physiological conditions (Kanwar
et al. 2010; Huo et al. 2010;L a n d i s - P i w o w a re ta l .2007).
However, their epigenetic roles in cancer prevention and
therapy have not yet been reported.
Although various studies have shown that green tea
polyphenol or EGCG can effectively inhibit carcinogenesis
in various animal organs (Tran et al. 2010; Liang et al.
2010; Sagara et al. 2010; Zhang et al. 2010), their
epigenetic effects have been largely undetermined. Morey
Kinney et al. (2009) demonstrated that administration of
0.3% green tea polyphenols (GTPs) to wild-type (WT) and
transgenic adenocarcinoma of mouse prostate (TRAMP)
mice showed no alteration in 5-methyl-deoxycytidine
(5mdC) levels in prostate, gut, and liver from WT mice at
both 12 and 24 weeks of age, with the single exception of a
decrease of 5mdC in the liver at 12 weeks. Quite
surprisingly,GTPstreatmentdidnotinhibittumorprogression
inTRAMPmice,althoughknownpharmacodynamicmarkers
ofGTPssuchasSsat and Clustrin mRNA levels were altered
in both WT and TRAMP prostates. However, Mittal et al.
(2003) demonstrated that topical application of EGCG
inhibits ultraviolet-B (UVB)-induced photocarcinogenesis
by UVB-induced global DNA hypomethylation in SKH-1
hairless mouse model system. Both immunohistochemical
analyses of 5mdC and DNMTs activities were restored
significantly by topical application of EGCG in a chronic
UVB-induced SKH-1 hairless mouse model system (Mittal
et al. 2003). Studies have strongly correlated dietary habits
and physical activity in relation to epigenetic reactivation of
several genes, including tumor suppressor genes (Yuasa et al.
2009; Yun et al. 2010a). Yuasa et al. (2005)d e m o n s t r a t e di n
primary gastric carcinoma patients that past life style and
dietary habits including consumption of cruciferous vegeta-
bles and GTPs alter the methylation status of several genes
such as CDX2 and BMP-2,w h i c ha r ei m p o r t a n tf o r
preventing gastric carcinogenesis. Recently, Volate et al.
(2009) showed that administration 0.6% (w/v)G T P si n
drinking water to azoxymethane-treated Apc Min/+ mice
showed a significant decrease in CpG methylation in the
retinoic X receptor alpha gene promoter leading to inhibition
of intestinal tumorigenesis.
Histone modifications
The disruptions of histone acetylation/deacetylation balances
by bioactive components through regulation of HAT and
HDAC activities have received considerable attention in
cancer prevention and therapy. In addition to DNA methyl-
ationinhibitoryactivity,EGCGalsoregulatesgeneexpression
through changes in histone modifications. Recently, Choi et
al. (2009) discovered that EGCG has strong HAT inhibitory
activity among all other catechins screened in various cell
extracts from B lymphocytes, and the order of HAT
inhibition by catechins is EGCG > EGC > EC. In the same
study, it was discovered that EGCG abrogates p300-induced
p65 acetylation in vitro and in vivo, increases the level
of cytosolic IκBα, and suppresses tumor necrosis factor
α-induced NF-κB activation. EGCG-induced p65 deace-
tylation events led to a cytoplasmic accumulation of
IκBα and subsequent cytosolic sequestration of NF-κB
resulting in the downstream inhibition of inflammatory
genes such as IL-6, COX-2, and NOS2 ( C h o ie ta l .2009).
Further, they found that EGCG does not make any
significant changes in HDACs, HMTs, and SIRT1 in their
assay system. However, studies with human prostate
cancer LNCaP cells showed that exposure to 1–10 μg/ml
of GTPs for 1–7 days caused time-dependent inhibition of
HDAC1-3 expression and increased the levels of acetylat-
ed histone H3 (LysH9/18) and H4 levels (Pandey et al.
2010). GTPs-induced histone acetylation and promoter
demethylation reactivated the GSTP1 gene, which is an
important hallmark in prostate tumorigenesis.
Studies have also been initiated using combinations of
GTPs with known HDAC inhibitors to enhance DNMT
inhibition and HDAC inhibition activities, respectively, for
effective chemoprevention (Nair et al. 2008). Recently, Nihal
et al. (2010) showed that combined use of GTPs with
vorinostat, known as SAHA, a HDAC inhibitor, imparts
significant anti-proliferative effects against human melanoma
cells. The demethylating activity of EGCG may synergize
with the HDAC inhibitory action of vorinostat to help
de-repress silenced tumor suppressor genes regulating
key functions such as proliferation and cell survival. In
keeping with this view, they showed a greater anti-melanoma
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either agent alone (Nihal et al. 2010). There is very limited
evidence regarding in vivo histone modification effects of
GTPs. A study with dimethylaminoazobenzene-induced
hepatocarcinogenesis in male Sprague–Dawley rats showed
that administration of 0.05% (w/w) Polyphenon E (from
black tea polyphenol) induced a significant decrease in
HDAC1 expression compared to animals fed a control diet
(Murugan et al. 2009).
Sulforaphane
Sulforaphane (SFN), an isothiocyanate naturally rich in
widely consumed cruciferous vegetables such as broccoli,
broccoli sprouts, cabbage, and kale, has been shown to
reduce the risk of developing many common cancers
(Higdon et al. 2007; Pledgie-Tracy et al. 2007; Keum et
al. 2009; Cheung and Kong 2010). SFN mediates chemo-
prevention through several mechanisms including cell cycle
arrest and induction of apoptosis and phase 2 detoxification
enzymes (Bryant et al. 2010; Chu et al. 2009; Dinkova-
Kostova et al. 2007; Bacon et al. 2003). However, there has
been growing interest in epigenetic regulation by SFN in
chemoprevention due to its histone deacetylase (HDAC)
inhibition activity (Myzak et al. 2007; Dashwood and Ho
2007; Ho et al. 2009). The HDAC inhibition activity of
SFN has been shown to lead to an increase in the global
and local histone acetylation status of a number of genes
(Bhamre et al. 2009; Telang et al. 2009; Dashwood and Ho
2008). SFN-mediated epigenetic alterations are believed to
be strongly involved in the process of cancer chemo-
prevention by altering the expression of various genes,
including tumor suppressor genes in various cancers
(Herman-Antosiewicz et al. 2007).
SFN was found to inhibit DNMTs in MCF-7 and MDA-
MB-231 breast cancer as well as CaCo-2 colon cancer cells
(Meeran et al. 2010; Traka et al. 2005). Meeran et al. (2010)
demonstrated that SFN treatment dose- and time-dependently
inhibited human telomerase reverse transcriptase (hTERT),
the catalytic regulatory subunit of telomerase, in both MCF-7
and MDA-MB-231 human breast cancer cells and that it had
negligible effects on normal control cells. Further, DNA
methyltransferases (DNMTs), especially DNMT1 and
DNMT3a, were also decreased in SFN-treated breast
cancer cells. More interestingly, down-regulation of
DNMTs induced site-specific CpG demethylation occurring
primarily in the first exon of the hTERT gene thereby
facilitating CTCF binding associated with hTERT repression
followed by cellular apoptosis in breast cancer cells (Meeran
et al. 2010).
SFN has also been found to have HDAC inhibitory
activity in many other cancer in vitro and in vivo cancer
models. SFN dose-dependently increased the activity of a
beta-catenin-responsive reporter (TOPflash) and diminished
HDAC activity in human embryonic kidney 293 cells
(Myzak et al. 2004). In HCT116 human colorectal cancer
cells, SFN inhibited HDAC activity thereby increasing
histone acetylation at the p21
WAF1/CIP1 promoter to enhance
its expression (Myzak et al. 2004). Human prostate cancer
BPH-1, LNCaP, and PC-3 cells also showed significant
inhibition of HDAC activity by SFN treatment. Further,
SFN-induced histone acetylation increased the expression
of the p21
WAF1/CIP1 protein, thereby inhibiting cell cycle
arrest and inducing cellular apoptosis in these prostate
cancer cell lines (Myzak et al. 2006b; Ho et al. 2009).
SFN also has HDAC inhibitory effects in vivo as shown
in animal and human models. Myzak et al. (2006a)
demonstrated that mice treated with a single oral dose of
10 μM SFN had significant HDAC inhibitory activity in
colonic mucosa with increased acetylated histones H3 and
H4. Further, the authors demonstrated that increased
acetylation enhanced the expression of p21
WAF1/CIP1 and
bax gene expressions, thereby suppressing tumorigenesis
in Apc/+ mice (Myzak et al. 2006a). Another study
demonstrated that administration of 7.5 μM SFN per
animal for 21 days significantly reduced prostate cancer
PC-3 tumor xenografts by inhibiting HDAC activity in
vivo (Myzak et al. 2007). Importantly, in human subjects,
a single dose of 68 g of broccoli sprouts inhibited HDAC
activity significantly in peripheral blood mononuclear
c e l l sa t3a n d6hf o l l o w i n gc o n s u m p t i o n( M y z a ke ta l .
2007). Following oral dosing, sulforaphane metabolites
were readily measurable in human breast tissue enriched
for epithelial cells (Cornblatt et al. 2007). Collectively,
SFN has been found to be a potent HDAC inhibitor both
in vitro and in vivo models.
Genistein
Genistein is an isoflavone belonging to the flavonoids
group of compounds and is found in a number of plants
including fava beans, soybeans, lupin, kudzu, and psoralea.
Genistein and other isoflavones have been found to have
anti-cancer and anti-angiogenic properties in various cancers.
Several studies have found moderate doses of genistein to
have inhibitory effects on cancers of the prostate, cervix,
brain, breast, and colon (Barnes 1995). It is becoming
increasingly clear that genistein exerts multiple effects on
cancer cell growth. Several mechanisms for the anti-
proliferative and anti-cancer properties of genistein have been
found, including prevention of DNA mutation, reduction in
cancer cell proliferation, inhibition of angiogenesis, and
induction of cellular apoptosis (Singh et al. 2006;G ue ta l .
2005;S ue ta l .2005; Sasamura et al. 2004). One potential
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is that genistein is involved in regulation of gene transcription
or silencing activity by modulating epigenetic events such as
DNA methylation and/or chromatin modifications (Li and
Tollefsbol 2010;L ie ta l .2009a;K i k u n oe ta l .2008).
Several reports have found that genistein has DNA
methyltransferase inhibitory activity as well as histone
modification properties in cancer cells. In prostate cancer
cells, genistein induced the expression of the tumor
suppressor genes p21
WAF1/CIP1 and p16
INK4a by altering
promoter methylation and histone modification (Majid et al.
2008; Kikuno et al. 2008). Further, it was found that
genistein increased acetylated histones 3 and 4 and H3-
lysine4 at the p21
WAF1/CIP1 and p16
INK4a transcription start
sites, mediated by induction of HATs. Genistein-mediated
promoter hypomethylation and hyperacetylation reactivate
expression of tumor suppressor genes in human prostate
cancer cells and are followed by cell cycle arrest and
cellular apoptosis induced by cyclin and caspase pathways,
respectively (Majid et al. 2008; Kikuno et al. 2008). This
dietary bioactive compound also reactivates BTG3, a tumor
suppressor gene, in A498, ACHN, and HEK-293 renal
carcinoma cell lines (Majid et al. 2009). Genistein activates
the epigenetic re-expression of BTG3 by altering promoter
DNA methylation through inhibition of DNMTs and
methyl-CpG-binding domain 2 in these cells, whereas,
genistein also increases histone acetylation by enhancing
HATactivity, followed by enrichment of acetylated histones
3 and 4, dimethyl-H3K4, and trimethyl-H3K4 near the
transcription start site at the BTG3 gene promoter (Majid et
al. 2009). This is consistent with other reports that genistein
upregulated mRNA expression of the BRAC1, p16
INK4a,
RARb, MGMT, and p21
WAF1/CIP1 genes (Majid et al. 2008;
Fang et al. 2005). Studies have also shown that genistein in
combination with other DNA methyltransferases or HDAC
inhibitors enhanced the reactivation of methylation-silenced
genes (Raynal et al. 2008; Li et al. 2009a; Fang et al. 2005).
Genistein not only reactivates tumor suppressor genes
through epigenetic modifications but also inhibits the
expression of tumor promoter genes such as hTERT.
Genistein inhibits DNMT1, DNMT3a, and DNMT3b and
enriches inactivating histone trimethyl-H3K9 followed by
transcriptional repression of hTERT expression in human
breast cancer cells (Li et al. 2009a). In another study with
MDA-MB-468 human breast cancer cells, low concentrations
of genistein partially demethylated the GSTP1 tumor
suppressor gene promoter and reactivated its expression
(King-Batoon et al. 2008).
In addition to in vitro epigenetic modulation, genistein-
treated neonatal CD-1 mice showed anomalously hypome-
thylated nucleosomal binding protein-1 promoter than
hypermethylated control (non-genistein) treated mice (Tang
et al. 2008). In contrast to genistein-induced DNA
hypomethylation mediated through DNMT inhibition,
studies also have shown that genistein induced hyper-
methylation in some animal models (Day et al. 2002;
Guerrero-Bosagna et al. 2008). In accordance with animal
studies, genistein also increased hypermethylation in
human studies randomized with selective cancer-related
genes. Thirty-four healthy premenopausal women were
randomized to take 40 or 140 mg isoflavones daily through
one menstrual cycle, and the methylation status of p16
INK4a,
RASSF1A, RARβ2, ER and CCND2 were assessed in
intraductal specimens. The results showed that RARβ2
and CCND2 were hypermethylated after genistein admin-
istration, and these results correlated well with serum
genistein levels (Qin et al. 2009).
Curcumin
Curcumin, a yellow pigment present in the spice turmeric
(Curcuma longa), has been linked with multiple beneficial
activities including anti-inflammatory, anti-angiogenic and
wound-healing, antioxidant, and anti-cancer properties.
Curcumin has been shown in various animal models and
human studies to be extremely safe even at very high doses;
however, their solubility and bioavailability is an obstacle
for therapeutic drug development (Aggarwal et al. 2003;
Shishodia et al. 2007). Curcumin-mediated chemopreven-
tion is mainly facilitated through cell cycle arrest and
induction of cellular apoptosis in various cancer cells.
Curcumin-induced apoptosis is involved with the intrinsic
and extrinsic apoptosis pathways, the NF-κB-mediated
pathway as well as the PI3K/Akt signaling pathway
(Reuter et al. 2008). Recent evidence has shown that
curcumin also inhibits DNMT activities and histone
modification such as HDAC inhibition in tumorigenesis
(Fu and Kurzrock 2010).
Molecular docking of the interaction between curcumin
and DNMT1 suggested that curcumin covalently blocks the
catalytic thiolate of C1226 of DNMT1 to exert its inhibitory
effect (Liu et al. 2005). This inhibition seems to be
comparatively lower than other bioactive dietary components
such as EGCG and genistein (Fang et al. 2007; Liu et al.
2005). Further, curcumin treatment with extracted genomic
DNA from a leukemia cell line induced global hypomethy-
lation (Liu et al. 2005). These results provide strong
evidence that curcumin is a potent DNA hypomethylating
agent, which is important for its broad-spectrum inhibitory
activity in inflammation, cancer, and many other diseases.
Curcumin also has strong inhibitory activity against
HDACs and HATs in several in vitro cancer models.
Curcumin showed strong proliferation inhibition potency
on Burkitt’s lymphoma Raji cells in vitro, with the IC50
value for 24 h at 25 μM. Significant decreases in the
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detected after treatment with curcumin followed by preven-
tion of IkappaB alpha degradation and inhibition of nuclear
translocationofthe NF-κB/p65subunit (Chenetal.2007;L i u
et al. 2005). Meja et al. (2008) demonstrated that even very
low concentrations of curcumin (30 and 200 nM) restored
corticosteroid function in human monocytes exposed to
oxidants. This occurred by maintaining HDAC2 activity via
preventing oxidant-induced degradation of HDAC2 through
down-regulating gene expression associated with protein
degradation.
Curcumin has been identified as a strong inhibitor for
HATs in both in vitro and in vivo cancer models. One of the
early epigenetic studies showed that curcumin is a specific
inhibitor of p300/CREB-binding protein (CBP) HAT
activity but not of p300/CBP-associated factor, in vitro
and in vivo. Curcumin-mediated p300/CBP inhibition was
associated with repression of histones H3 and H4 and non-
histone protein such as p53 and HIV-TAT proteins
(Balasubramanyam et al. 2004). Another structural analysis
study done by Marcu et al. (2006) revealed that alpha, beta
unsaturated carbonyl groups in the curcumin side chain
function as Michael reaction sites, which is required for
its HAT inhibitory activity. Further, they demonstrate that
curcumin selectively promotes proteasome-dependent
degradation of p300 and closely related CBP protein
without affecting the HATs such as PCAF or GCN5 in
prostate PC3-M and peripheral blood lymphocytes.
Interestingly, curcumin was able to effectively block
histone hyperacetylation in both PC3-M prostate cancer
cells and peripheral blood lymphocytes induced by the
HDAC inhibitor MS-275 (Marcu et al. 2006).
Kang et al. (2006) showed a strong inhibition of
curcumin-mediated HAT inhibitory activity associated with
a decrease in histone H3 and H4 acetylation in brain cancer
cells. Further, curcumin-induced histone modifications
associated with caspases-mediated cellular apoptosis in
brain cancer cells and enhanced neurogenesis, synaptogene-
sis, and migration of neural progenitor cells in brain-derived
adult neural stem cells in vitro (Kang et al. 2006). Another
study demonstrated that curcumin restored ultraviolet
radiation-induced hyperacetylation in the promoter region
of ATF3, COX2,a n dMKP1, which are inflammatory-related
genes in human keratinocytes (Pollack et al. 2009). Further,
studies have also shown that curcumin-mediated promoter
hypoacetylation of certain genes was strongly correlated
with gene silencing (Cui et al. 2007; Pollack et al. 2009). A
very recent study showed that curcumin inhibits high
glucose-induced proinflammatory cytokines by epigenetic
modification in human monocytic (THP-1) cells. It was
demonstrated that curcumin treatment significantly reduced
HAT activity, p300 and acetylated CBP/p300 gene expres-
sion, and induced HDAC2 expression in THP-1 cells,
thereby inhibiting high glucose-induced proinflammatory
cytokines, which is an important molecular target in reducing
diabetic complications (Yun et al. 2010b).
In animal models, curcumin is found to be protective
against cardiac failure, inflammation, and fibrosis through
down-regulation of NFκB, GATA4, and TGFβ signaling
as well as inhibition of HAT activity in rats (Morimoto et
al. 2008;L ie ta l .2008). Curcumin was also found to be
very effective against streptozotocin-induced diabetes in
male Sprague–Dawley rats through the inhibition of H3
hyperacetylation, NFκB binding, and p300 and H3S10
phosphorylation (Chiu et al. 2009; Tikoo et al. 2008).
Resveratrol
Resveratrol is a dietary polyphenol derived from grapes,
berries, peanuts, and other plant sources. Resveratrol was
found to have strong anti-cancer properties by modulating
signal transduction pathways that control cell division and
growth, apoptosis, inflammation, angiogenesis, and metasta-
sis (Bishayee 2009). The anti-cancer property of resveratrol
has been supported by its ability to inhibit proliferation of a
wide variety of human tumor cells such as in skin, breast,
prostate, lung, and colon (Mao et al. 2010; Vanamala et al.
2010; Liu et al. 2010; Kraft et al. 2009). These in vitro
results have led to numerous preclinical animal studies to
evaluate the potential of this drug for cancer chemopreven-
tion and chemotherapy. Multiple biochemical and molecular
actions seem to contribute to resveratrol effects against
precancerous or cancer cells (Athar et al. 2009).
Resveratrol has been shown to have weaker DNMT
inhibitory activity than other dietary bioactive components
such as EGCG. Resveratrol prevents epigenetic silencing of
BRCA-1 induced by aromatic hydrocarbon receptor (AHR)
in MCF-7 human breast cancer cells (Papoutsis et al. 2010).
It was demonstrated that AHR-mediated enrichment of
mono-methylated-H3K9, DNMT1, and methyl-binding
domain protein-2 at BRCA-1 promoter was restored, at
least partially by resveratrol treatment, which was associated
with BRAC-1 reactivation in MCF-7 cells (Papoutsis et al.
2010). In contrast, resveratrol did not significantly induce
retinoic acid receptor beta 2 (RARβ 2) expressions by
inhibiting RARβ2 promoter methylation in MCF-7 cells
compared to other adenosine analogs (Stefanska et al. 2010).
Studies have shown that resveratrol is associated with
activation of the type III HDAC inhibitors, sirtuin 1
(SIRT1), and p300, in multiple in vitro and in vivo models
(Kaeberlein et al. 2005). The activated SIRT1 negatively
regulates Survivin expression through its deacetylase
activity. Wang et al. (2008) found that human BRCA1-
associated breast cancers have lower levels of SIRT1
expression.However,bioactivedietarycomponentsassociated
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human BRAC1 by altering H3 acetylation, which is an
important strategy for targeted therapy for BRCA1-
associated breast cancer (Wang et al. 2008). In addition,
SIRT1-associated BRAC1 signaling is important for inhibit-
ing tumorigenesis by activating oncoproteins in human breast
cancer cells (Wang et al. 2008). It was shown in APC/+ mice
that SIRT1-encoded proteins are required for resveratrol-
mediated chemoprevention (Boily et al. 2009). SIRT1 also
plays important roles in aging processes, since SIRT1-null
mice could not tolerate caloric restriction and did not extend
their lifespan compared to control mice (Boily et al. 2008).
Other bioactive components
In addition to the aforementioned bioactive components,
other common fruits and vegetables have also been reported
to have epigenetic targets either through DNMT inhibition
or histone modifications. These bioactive compounds
include apigenin (parsley), baicalein (Indian trumpet),
cyanidins (grapes), isothiocyanate (cruciferous vegetables),
rosmarinic acid (rosemary), and silymarin (milk thistle). All
of these bioactive components have been reported to have
either direct or indirect epigenetic targets in cancer chemo-
prevention and therapy (Davis and Ross 2007;F a n ge t
al. 2007; Paluszczak et al. 2010; King-Batoon et al. 2008;
Li and Tollefsbol 2010).
Conclusion and future directions
The emerging field of nutritional genomics targets nutrient-
related genetic and epigenetic changes for prevention and
therapy of various diseases including cancer. From the
studies described herein, it is clear that bioactive dietary
components hold great potential not only in the prevention
but also in the therapy of a wide variety of cancers by
altering various epigenetic modifications. Cancer is a multi-
step processes and uses many survival pathways to prevail
over normal cells. Therefore, bioactive components which
have numerous molecular targets and suppress multiple
cellular pathways such as EGCG may have strong potential
for cancer prevention and treatment. Although individual
bioactive components have shown great potential in
prevention and treatment of various cancers, the combined
use of dietary components should be more efficient in
targeting the many cellular processes involved in tumori-
genesis. Additional clinical studies are required to analyze
the safety profile of doses, route of administration, organ
specificity, and bioavailability of these bioactive components
in human subjects. Ancient medicinal uses and extant
scientific evidence strongly endorse the use of these bioactive
dietary components for drug discovery and development
against cancer prevention and therapy.
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